Akademik Veri Yönetim Sistemi
LATIN AMERICAN JOURNAL OF PHARMACY, cilt.35, ss.1169-1176, 2016 (SCI-Expanded)
Liv-52 has hepatoprotective effect and may be beneficial for desflurane hepatotoxicity. We aimed to investigate the prophylactic or therapeutic effects of Liv-52 on hepatotoxicity induced desflurane. The study was designed into seven groups as healthy group (HG), desflurane control groups (DCG-1, DCG-2, and DCG-3), Liv-52 treatment after desflurane (DLG), Liv-52 treatment before desflurane group (LDG), and Liv-52 treatment before and after desflurane group (LDLG). Desflurane was adjusted as to 6 % concentration for two hours. Liv-52 was given 20 mg/kg. Alanine transaminase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), malondialdehyde (MDA), and total glutathione (tGSH) levels were measured. MDA, tGSH, ALT, AST, and LDH levels of DLG, LDG, and LDLG were found statistically significant compared to controls and healthy groups (p < 0.05). But the differences between HG and LDLG for both MDA, tGSH, ALT, AST, and LDH parameters were found statistically insignificant (p > 0.05). Pathological findings such as sinusoidal dilatation congestion and inflammation areas were observed in control groups but not in LDLG. Both prophylactic and therapeutic uses of Liv-52 may be the most appropriate methods to be minimized desflurane-induced hepatotoxicity.